Avsnitt

  • In this episode, Christopher L. Bowlus, MD, discusses recent advances in the management of primary biliary cholangitis (PBC), including:

    Treatment goalsUse of PPAR agonists for the treatment of PBCClinical trial results for elafibranor (ELATIVE), seladelpar (RESPONSE), and bezafibrate (BEZURSO)

    Presenter:

    Christopher L. Bowlus, MD
    Lena Valente Professor and Chief
    Division of Gastroenterology and Hepatology
    University of California Davis School of Medicine
    Sacramento, California

    Link to full program:
    https://bit.ly/41tvSDu

    Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

  • Listen as Elizabeth Kircher, DNP, and R. Hal Scofield, MD, discuss best practice approaches for the treatment of Sjögren’s syndrome and what’s on the horizon for future therapeutic options.

    Topics include:

    Challenges in Sjogren’s Syndrome Diagnosis and Patient Understanding: Difficulties in explaining Sjogren’s syndrome diagnosis to patients unfamiliar with it and challenges in addressing the disease’s varied symptomsPatient Education and Communication: Strategies to prevent overwhelming patients during early visits and effective ways to address misconceptionsDiagnostic Challenges and Misunderstandings: Differences between clinical and research criteria for diagnosis and the importance of understanding eachUse of Ultrasound and Biopsy in Diagnosis: Benefits and limitations of ultrasound and biopsies in diagnosing Sjogren’s syndromeMultidisciplinary Care Barriers: Challenges in coordinating care among specialists such as ophthalmologists, dentists, and rheumatologistsSymptomatic vs Disease-Modifying Treatments: Strategies for managing symptoms vs addressing the underlying disease with medicationsLong-term Medication and Risks: Considerations when prescribing long-term medications and immunosuppressive therapiesResearch and Emerging Therapies: Developments in Sjogren’s syndrome research, including promising medications in clinical trialsGuideline Development and Patient Reassurance: The role of professional guidelines in shaping care and providing patients with reassurancePolypharmacy and Medication Reconciliation: The importance of pharmacist involvement in managing complex medication regimens for older patients

    Faculty:

    Elizabeth Kircher, DNP

    R. Hal Scofield, MD
    Member/Professor, Arthritis & Clinical Immunology
    Oklahoma Medical Research Foundation
    Professor, Department of Medicine, College of Medicine
    University of Oklahoma Health Sciences Center
    Associate Chief of Staff for Research
    Oklahoma City US Department of Veterans Affairs Medical Center
    Oklahoma City, Oklahoma

    Link to full program:
    https://bit.ly/3YKpsOE

  • Saknas det avsnitt?

    Klicka här för att uppdatera flödet manuellt.

  • In this CCO Nephrology podcast episode, hear from nephrologists Pietro Canetta, MD, MS, and Andy Bomback, MD, PhD, experts in clinical management and research on glomerular diseases as they discuss key updates in managing IgAN. Faculty highlight the importance of a comprehensive supportive care regimen to protect patients’ kidneys and prevent progression of disease. In addition, they review the merits and place in therapy of novel and emerging therapies.

    Topics include:

    Supportive care as the foundation of IgAN managementPlace in therapy for new and emerging agentsTargeted-release formulation of budesonideEndothelin receptor antagonists (eg, sparsentan)Factor B inhibitors (eg, iptacopan)The role of clinical trial involvement

    Learn more about IgA nephropathy with educational activities and resources here:

    CME-certified text module with animated pathophysiology video and patient voice audio clipClinicalThought commentariesResources on IgAN from the American Kidney Fund
  • In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.  

     Episode outline:  

    Colchicine: inhibition of NLRP3 inflammasome assembly/activationCanakinumab (anti–IL-1β monoclonal antibody)Ziltivekimab (anti–IL-6 monoclonal antibody)Other emerging targets/therapies

    To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:  

    CME-certified text module with animated pathophysiology video and faculty voice audio clips ClinicalThought commentaries Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD
  • In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore new and emerging strategies to target residual risk associated with systemic inflammation in patients with ASCVD and CKD.  

     Episode outline:  

    The relationship among systemic inflammation, ASCVD, and CKD The role of cardiologists and nephrologists in screening and mitigating systemic inflammation

    To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:  

    CME-certified text module with animated pathophysiology video and faculty voice audio clips ClinicalThought commentaries Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD
  • In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore the pathophysiology and novel therapeutic strategies to target residual inflammatory risk associated with ASCVD and CKD.  

     Episode outline:  

    Moving beyond lipid lowering to address residual inflammatory riskNovel anti-inflammatory targets for ASCVD

    To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:  

    CME-certified text module with animated pathophysiology video and faculty voice audio clipsClinicalThought commentariesPodcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD
  • In this CCO Nephrology podcast episode, hear from Kelly Chen, a nephrology nurse practitioner and patient living with IgA nephropathy, as she discusses her experiences with Dr Pietro Canetta, Associate Professor of Medicine at Columbia University and expert in glomerular diseases.

    Episode outline:

    Seeking and obtaining an IgAN diagnosis Patient self-advocacy Individualizing IgAN treatment plansClinical trial involvement Burdens of IgAN: physical, emotional, social, and beyond

    To learn more about IgA nephropathy, find more educational activities and resources with the links below:

    CME-certified text module with animated pathophysiology video and patient voice audio clipsClinicalThought commentaries Resources on IgAN from the American Kidney Fund
  • In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:

    Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatment

    Presenters:

    Mark S. Sulkowski, MD, FIDSA, FAASLD
    Professor of Medicine
    Director, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center
    Johns Hopkins University School of Medicine
    Baltimore, Maryland

    Tatyana Kushner, MD, MSCE
    Associate Professor
    Division of Liver Diseases
    Icahn School of Medicine at Mount Sinai
    New York, New York

    Paul Y. Kwo, MD
    Professor of Medicine
    Director of Hepatology
    Stanford University School of Medicine
    Palo Alto, California

    Jacki Chen, PhD
    Patient Advocate

    Link to full program:
    https://bit.ly/3TuqFHI

    Link to the slides:
    https://bit.ly/4a60GM4

    Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

  • In this episode, Arun B. Jesudian, MD, and Mazen Noureddin, MD, MHSc, discuss the expert-informed clinical pathway for the multidisciplinary care of patients with MASLD or MASH, current and emerging therapeutics, and management optimization strategies.

    Presenters:

    Arun B. Jesudian, MD
    Associate Professor of Clinical Medicine
    Division of Gastroenterology and Hepatology
    Weill Cornell Medicine
    New York, New York

    Mazen Noureddin, MD, MHSc
    Professor of Medicine
    Houston Methodist Hospital
    Director
    Houston Research Institute
    Houston, Texas

    Content based on an online CME program supported by independent educational grants from Novo Nordisk.

    To view the full program on “Clinical Pathways: Multidisciplinary Approach to Managing Metabolic Dysfunction‒Associated Steatohepatitis,” including 4 CME/CE-certified text modules with accompanying slidesets, 4 ClincalThought commentaries, and a downloadable infographic resource on the AGA MASLD MASH Clinical Care Pathway, visit clinicaloptions.com or click on the link below.

    Link to full program:
    https://bit.ly/3Tyu7At

  • In this episode, Jennifer Green, MD, and Carol Hatch Wysham, MD, break down the latest headlines on incretin-based therapies and how to address these topics with patients. Their discussion includes:

    Beneficial effects beyond glycemic control Adverse events and how to manage themNon- or partial responders and the importance of setting expectations with patients Weight rebound when discontinuing therapyMedication access issues related to cost and drug availability

    Presenters:

    Jennifer Green, MD
    Professor of Medicine
    Division of Endocrinology and Duke Clinical Research Institute
    Duke University School of Medicine
    Durham, North Carolina

    Carol Hatch Wysham, MD
    Clinical Professor of Medicine
    Clinical Endocrinologist
    MultiCare/Rockwood Clinic
    Spokane, Washington

    Link to online program:
    https://bit.ly/48b6XnW

  • In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:

    Updated CDC recommendations for one-time universal screening for HBVAddressing patient-, provider-, and system-level barriers to universal HBV screeningBest practices for implementation of HDV screening

    Presenters:

    Douglas Dieterich, MD
    Director, Institute for Liver Medicine

    Professor of Medicine

    Division of Liver Diseases

    Mount Sinai School of Medicine

    New York, New York

    Camilla S. Graham, MD, MPH
    Co-Director, Viral Hepatitis Clinic
    Division of Infectious Diseases
    Beth Israel Deaconess Medical Center
    Harvard Medical School
    Boston, Massachusetts

    Robert Wong, MD, MS
    Clinical Associate Professor
    Division of Gastroenterology and Hepatology
    Stanford University School of Medicine
    Palo Alto, California

    Link to full program:
    https://bit.ly/3TuqFHI

    Link to the slides:
    https://bit.ly/4atS42z

  • In this podcast episode, Aline Charabaty, MD, AGAF, FACG, and Marla Dubinsky, MD, discuss how women in gastroenterology (GI) can find their “friendtors” and build a strong network of mentors, sponsors, and allies. Although there may be many barriers for women in the GI medicine specialty, these experienced leaders have useful tips to help emerging healthcare professionals avoid internalizing these challenges and strategically focus on accomplishing their goals.

    Presenters:

    Dr Aline Charabaty is an Assistant Professor of Medicine at Johns Hopkins School of Medicine, the Clinical Director of the IBD Centre at Johns Hopkins Sibley Memorial Hospital in Washington, DC, and the Co-Founder of Scrubs & Heels.

    Aline Charabaty, MD, AGAF, FACG: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Takeda.

    Dr Marla Dubinsky is a Professor of Pediatrics and Medicine at Mount Sinai in New York, Chief of Division of Pediatric GI and Nutrition at Mount Sinai Kravis Children's Hospital, and the Co-Director of the Susan and Leonard Feinstein IBD Clinical Centre. Dr Dubinsky is also the Director of the Marie and Barry Lipman IBD Preconception and Pregnancy Clinic. She is also an innovator and the Co-Founder of Trellus Health, providing personalized resilience coaching for people living with IBD. She received the Sherman Prize in 2022, which recognized her outstanding achievement in the field of IBD. In addition, she served as the Co-Chair for our inaugural Scrubs & Heels Leadership Summit in 2022.

    Marla Dubinsky, MD: consultant/advisor/speaker: AbbVie, Abivax, AstraZeneca, Bristol Myers Squibb, Janssen, Lilly, Merck, Pfizer, Prometheus Biosciences, Takeda.

    Episode outline:

    Overview of barriers faced by women in GIImpact of failing to adequately address these barriersDefining the roles of mentors, sponsors, and alliesImportant qualities of mentors, sponsors, and alliesRole models vs peer mentors

    Other program activities:

    Full Program: Equipped and Empowered: Thriving as Women in GIPodcast 2: Embracing Your Value: Tools and Strategies for Optimizing Professional Growth and DevelopmentPodcast 3: Being Your Full Self: Pursuing Work–Life BalanceClinicalThought: Expert Commentary on Thriving as Women in GI

    After selecting the “Continue to Post Test” button:

    To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select 1 best answer for each question. When you have completed all the questions, press the "Continue" button at the bottom

  • In this podcast episode, Anita Afzali, MD, MPH, MHCM, FACG, AGAF, and Aja McCutchen, MD, discuss how women in gastroenterology (GI) can embrace and enhance their value. These inspiring GI medicine experts propose a practical formula that involves ongoing, careful self-reflection and asking yourself how your strengths, core values, and interests can be aligned with professional endeavors. In addition, self-advocacy and self-allyship can serve as harmonious tools to drive action and positive change.


    Presenters:

    Dr Anita Afzali is a Professor of Clinical Medicine, Interim Division Director of the Division of Digestive Diseases, Executive Vice Chair of Medicine in the Department of Internal Medicine, and the Associate Chief Medical Officer of the UC Health system in Cincinnati, Ohio. She is also a Co-Founder of Scrubs & Heels.

    Anita Afzali, MD, MPH, MHCM, FACG, AGAF: consultant: AbbVie, Bristol Myers Squibb, Gilead Sciences, Janssen, Lilly, Pfizer, Takeda; provider of non-CME/CE services: AbbVie, Janssen, Pfizer, Takeda.


    Dr Aja McCutchen is a Partner and Physician Executive at Atlanta Gastroenterology Associates, a division of United Digestive in Atlanta, Georgia, and served as Co-Chair at the Scrubs & Heels 2023 Leadership Summit.

    Aja McCutchen, MD: consultant/advisor/speaker: Eli Lilly, Modify Health, Redhill Biopharm, Sanofi Regeneron, Takeda.


    Episode outline:

    Understanding and establishing your own market value; bringing that to your own organizationConsequences of being ill-equipped to pursue professional growth and developmentAdvocating for the value you bring to the professionNegotiation as a form of self-allyshipNegotiation categories to help support career success and protect work–life balance

    Other program activities:

    Full Program: Equipped and Empowered: Thriving as Women in GIPodcast 1: Finding Your Friendtors: Mentors, Sponsors, and AlliesPodcast 3: Being Your Full Self: Pursuing Work–Life BalanceClinicalThought: Expert Commentary on Thriving as Women in GI


    To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select 1 best answer for each question. When you have completed all the questions, press the "Continue" button at the bottom.

  • In this podcast episode, Aline Charabaty, MD, AGAF, FACG, and Christina Tennyson, MD, DipABLM, discuss how women in gastroenterology (GI) can fight burnout and establish a work–life balance that meets their needs. Tune in to learn how to say no, about the importance of saying yes to meaningful things that will advance your career and bring you joy, and get essential tips for well-rounded and ongoing self-care.

    Presenters:
    Dr Aline Charabaty is an Assistant Professor of Medicine at Johns Hopkins School of Medicine, the Clinical Director of the IBD Centre at Johns Hopkins Sibley Memorial Hospital in Washington, DC, and the Co-Founder of Scrubs & Heels.

    Aline Charabaty, MD, AGAF, FACG: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Takeda.

    Dr Christina Tennyson is a gastroenterologist with expertise and certification in nutrition, lifestyle medicine, and integrative medicine. She started her career in academia at Columbia University in New York before joining the Augusta Health Digestive Wellness program in the Virginia Shenandoah Valley, where she is engaged in a multidisciplinary program that includes culinary medicine classes and farm workshops for patients.

    Christina Tennyson, MD, DipABLM, has no relevant financial relationships to disclose.

    [Link to: https://scrubsandheels.com/]

    Episode outline:

    Variables that contribute to burnoutStrategies to protect your timeVetting collaborative projectsRequesting flexible schedules, part-time work, maternity leaveCharting your own career pathPrioritizing personal timePreserving friendships, hobbiesLeave work at work

    Other program activities:

    Full Program: Equipped and Empowered: Thriving as Women in GI https://bit.ly/3Zmqy1I]Podcast 1: Finding Your Friendtors: Mentors, Sponsors, and Allies https://bit.ly/3LuKzO6Podcast 2: Embracing Your Value: Tools and Strategies for Optimizing Professional Growth and Development https://bit.ly/3RsFl9iClinicalThought: Expert Commentary on Thriving as Women in GI https://bit.ly/48oi5iS

    Link to CME: Claim Credit: https://bit.ly/48oi5iS

    [After selecting the “Continue to Post Test” button:]

    To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select 1 best answer for each question. When you have completed all the questions, press the "Continue" button at the bottom.

  • This podcast episode is part of a multimedia program discussing the impact of health disparities in anemia of chronic kidney disease (CKD) on patient outcomes. Tune in to hear Santosh Saraf, MD, and Milda Saunders, MD, MPH, highlight mitigation strategies to improve screening and management. The overview will include:

    The definition of CKD and the relative prevalence in specific minority groupsHow health disparities affect CKD-related clinical and patient outcomesAppropriate screening techniques to diagnose patients with anemia of CKDStrategies to address health disparities to improve patient outcomes in the management of anemia of CKD

    Presenters:

    Santosh Saraf, MD
    Associate Professor of Medicine
    Division of Hematology and Oncology
    Department of Medicine
    University of Illinois at Chicago
    Chicago, Illinois

    Milda Saunders, MD, MPH
    Associate Professor of Medicine
    Department of Medicine
    University of Chicago
    Chicago, Illinois

    To view other program offerings, including a CE-certified on-demand webcast, a ClinicalThought commentary, and to download slides, visit:
    https://bit.ly/3iL07S0

  • In this episode, listen as Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, answer key questions about identifying patients at high risk for lupus nephritis, whether an elevated serum creatinine always signals lupus nephritis, the safety of newer therapies for lupus in women who are pregnant or breastfeeding, and the possibility of using SGLT2 inhibitors in patients with lupus nephritis.

    Presenters:

    Karen H. Costenbader, MD, MPH
    Professor of Medicine
    Department of Medicine
    Harvard Medical School
    Director, Lupus Program
    Division of Rheumatology, Inflammation and Immunity
    Brigham and Women’s Hospital
    Boston, Massachusetts

    Brad H. Rovin, MD
    Professor and Director, Division of Nephrology
    The Lee A. Hebert Professor of Nephrology
    Medical Director, The Ohio State Center for Clinical Research Management
    The Ohio State University Wexner Medical Center
    Columbus, Ohio

    Review the downloadable slidesets at:
    https://bit.ly/3mlHOla

    Link to full program:
    https://bit.ly/3aC2NNL

  • In this episode, David S. Kountz, MD, discusses with Keith C. Ferdinand MD, FACC, FAHA, a patient case in which health disparities affected NVAF care and provides patient, provider, and health-system level strategies to address these disparities to improve NVAF-related cardiovascular outcomes.

    Presenters

    Keith C. Ferdinand, MD, FACC, FAHA
    Professor of Medicine
    Tulane Heart and Vascular Institute
    Tulane University School of Medicine
    New Orleans, Louisiana

    David S. Kountz, MD
    Professor of Medicine
    Department of Medicine
    Hackensack Meridian School of Medicine
    Nutley, New Jersey

    Link to full program:
    https://bit.ly/3MbIfZI

  • In this episode, Keith C. Ferdinand MD, FACC, FAHA, discusses with David S. Kountz, MD, a patient case in which health disparities affected NVAF care and provides strategies to address low health literacy and patient access to direct-acting oral anticoagulant to improve NVAF-related cardiovascular outcomes.

    Presenters

    Keith C. Ferdinand, MD, FACC, FAHA
    Professor of Medicine
    Tulane Heart and Vascular Institute
    Tulane University School of Medicine
    New Orleans, Louisiana

    David S. Kountz, MD
    Professor of Medicine
    Department of Medicine
    Hackensack Meridian School of Medicine
    Nutley, New Jersey

    Link to full program:
    https://bit.ly/3MbIfZI

  • In this episode, Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, discuss health disparities in systemic lupus erythematosus and lupus nephritis. Topics include:

    Disproportionate prevalence among marginalized groups in the United StatesLupus-related social determinants of healthChallenges with medication adherenceStrategies to reduce these disparities

    Presenters:

    Karen H. Costenbader, MD, MPH
    Professor of Medicine
    Department of Medicine
    Harvard Medical School
    Director, Lupus Program
    Division of Rheumatology, Inflammation and Immunity
    Brigham and Women’s Hospital
    Boston, Massachusetts

    Brad H. Rovin, MD
    Professor and Director, Division of Nephrology
    The Lee A. Hebert Professor of Nephrology
    Medical Director, The Ohio State Center for Clinical Research Management
    The Ohio State University Wexner Medical Center
    Columbus, Ohio

    This episode is part of a larger program titled, “Lupus and Lupus Nephritis: Improving Outcomes and Reducing Disparities.” To access the full program, follow this link:
    https://bit.ly/3PWAzNU

  • This podcast is the first in a series of 3 featuring an multidisciplinary panel of expert faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, David S. Kountz, MD, provides a detailed explanation of the atrial fibrillation paradox and data on the impacts of SDOH on NVAF CV-related outcomes.

    Review the downloadable slideset and the full program at:
    https://bit.ly/3yYXP8e